摘要
目的研究低分子肝素在ESRD患者行血液透析治疗中的安全性及对β2-M、Cr的影响。方法抽取66例ESRD患者,时间截取点为2016年1月~2019年12月,将其随机分成LMWH组和UFH组,每组33例,都采用血液透析治疗,LMWH组使用低分子肝素做为抗凝剂,UFH组使用常规肝素作为抗凝剂,连续治疗6个月。然后对比分析两组患者的并发症情况、血小板计数、脂质代谢情况、β2-M、Cr含量。结果 LMWH组患者脂质代谢紊乱得到改善,并发症发生率、β2-M、Cr含量明显少于UFH组(P <0.05);治疗后,两组患者的血小板计数比较,差异无统计学意义(P> 0.05)。结论低分子肝素在ESRD患者进行血液透析治疗中,血脂代谢紊乱得到改善、并发症少、抗凝疗效确切、更好地抑制体内炎症因子的表达,临床效果显著。
Objective To study the safety of low molecular weight heparin in patients with ESRD undergoing hemodialysis and its effect onβ2-M and Cr.Methods Sixty-six ESRD patients were selected from January 2016 to December 2019.They were randomly divided into LMWH groups and UFH groups.Each group of 33 patients was treated with hemodialysis.The dialysis time in the LMWH group was low.Molecular heparin was used as an anticoagulant,and the UFH group was treated with conventional heparin as an anticoagulant for 6 consecutive months.Then,the complications,platelet number,lipid metabolism,β2-M and Cr of the two groups of patients were compared and analyzed.Results Disorders of lipid metabolism in LMWH group patients were improved,and the incidence of complications,β2-M,and Cr levels were significantly lower than those in the UFH group(P<0.05).After treatment,the platelet numbers of the two groups were not significantly different(P>0.05).Conclusion Low molecular weight heparin in hemodialysis treatment of ESRD patients has improved blood lipid metabolism disorder,fewer complications,accurate anticoagulant effect,better inhibition of inflammatory factor expression in the body,and has significant clinical effects.
作者
林志鹏
LIN Zhi-peng(Hemodialysis room of Sichang Town Health Center,Jieyang 515549,China)
出处
《中国处方药》
2020年第12期107-108,共2页
Journal of China Prescription Drug
关键词
低分子肝素
ESRD患者
血液透析
Low molecular weight heparin
ESRD patients
Hemodialysis
